Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First PIP recommendation to broaden Cancidas' EU indication

This article was originally published in Scrip

Executive Summary

Merck & Co's antifungal Cancidas (caspofungin) is set to have its approved indications expanded in the EU to include paediatric patients following a positive opinion from the EU's CHMP– the first to be made based on clinical trial data generated in accordance with an agreed paediatric investigation plan (PIP). The echinocandin is currently approved in Europe for the treatment of several severe fungal infections, and is now approved for use in these infections in children aged 12 months to 17 years. The indications are: treatment of invasive candidiasis; treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B, and/or itraconazole; and empirical therapy for presumed fungal infections in febrile neutropenic patients. PIPs are agreed in advance by the European Medicines Agency Paediatric Committeeand are legally binding for companies developing medicinal products for use in the EU.

You may also be interested in...



Urovant’s Vibegron Flops In IBS Study

Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Catabasis’s Future In Doubt After DMD Phase III Failure

Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.

Topics

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel